Angiogenic impairment of the vascular endothelium: A novel mechanism and potential therapeutic target in muscular dystrophy

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 12, 2013, Pages 2867-2876

  Palladino, Mariangela ^a,b   Gatto, Ilaria ^b   Neri, Valentina ^a,b   Straino, Stefania ^c   Smith, Roy C ^a   Silver, Marcy ^a   Gaetani, Eleonora ^b   Marcantoni, Margherita ^b   Giarretta, Igor ^b   Stigliano, Egidio ^b   Capogrossi, Maurizio ^c   Hlatky, Lynn ^a   Landolfi, Raffaele ^b   Pola, Roberto ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Angiogenesis inhibitors; Endothelium, vascular; Muscle diseases, inflammatory; Nitric oxide synthase type III

Indexed keywords

ACETYLSALICYLIC ACID; CAVEOLIN 1; CYCLIC GMP; DYSTROPHIN; NITRIC OXIDE SYNTHASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; ENDOTHELIUM CELL; EXERCISE; IN VITRO STUDY; ISCHEMIA; LOW DRUG DOSE; MOUSE; MUSCLE CELL; MUSCULAR DYSTROPHY; MYOBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SATELLITE CELL; TUMOR GROWTH; VASCULAR ENDOTHELIUM; WILD TYPE;

ANGIOGENESIS INHIBITORS; ENDOTHELIUM, VASCULAR; MUSCLE DISEASES, INFLAMMATORY; NITRIC OXIDE SYNTHASE TYPE III;

ANIMALS; APOPTOSIS; ASPIRIN; CARCINOMA, LEWIS LUNG; CAVEOLIN 1; CELL AGING; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CORNEAL NEOVASCULARIZATION; CYCLIC GMP; DISEASE MODELS, ANIMAL; DYSTROPHIN; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ISCHEMIA; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; MYOBLASTS, SKELETAL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; TIME FACTORS;

EID: 84888199909     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.301172     Document Type: Article

References (34)

1. England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR, Zubrzycka-Gaarn EE, Bulman DE, Harris JB, Davies KE. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature. 1990;343:180-182
2. Rybakova IN, Patel JR, Ervasti JM. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol. 2000;150:1209-1214
3. Loufrani L, Matrougui K, Gorny D, Duriez M, Blanc I, Lévy BI, Henrion D. Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin. Circulation. 2001;103:864-870
4. Loufrani L, Levy BI, Henrion D. Defect in microvascular adaptation to chronic changes in blood flow in mice lacking the gene encoding for dystrophin. Circ Res. 2002;91:1183-1189
5. Loufrani L, Dubroca C, You D, Li Z, Levy B, Paulin D, Henrion D. Absence of dystrophin in mice reduces NO-dependent vascular function and vascular density: Total recovery after a treatment with the aminoglycoside gentamicin. Arterioscler Thromb Vasc Biol. 2004;24:671-676
6. Nico B, Roncali L, Mangieri D, Ribatti D. Blood-brain barrier alterations in MDX mouse, an animal model of the Duchenne muscular dystrophy. Curr Neurovasc Res. 2005;2:47-54
7. Asai A, Sahani N, Kaneki M, Ouchi Y, Martyn JA, Yasuhara SE. Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS One. 2007;2:e806
8. Thomas GD, Ye J, De Nardi C, Monopoli A, Ongini E, Victor RG. Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy. PLoS One. 2012;7:e49350
9. Verma M, Asakura Y, Hirai H, Watanabe S, Tastad C, Fong GH, Ema M, Call JA, Lowe DA, Asakura A. Flt-1 haploinsufficiency ameliorates muscular dystrophy phenotype by developmentally increased vasculature in mdx mice. Hum Mol Genet. 2010;19:4145-4159
10. Kearney JB, Ambler CA, Monaco KA, Johnson N, Rapoport RG, Bautch VL. Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division. Blood. 2002;99:2397-2407
11. Miyazaki D, Nakamura A, Fukushima K, Yoshida K, Takeda S, Ikeda S. Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers. Hum Mol Genet. 2011;20:1787-1799
12. Palladino M, Gatto I, Neri V, Straino S, Silver M, Tritarelli A, Piccioni A, Smith RC, Gaetani E, Losordo DW, Crea F, Capogrossi M, Pola R. Pleiotropic beneficial effects of sonic hedgehog gene therapy in an experimental model of peripheral limb ischemia. Mol Ther. 2011;19:658-666
13. Biscetti F, Gaetani E, Flex A, Aprahamian T, Hopkins T, Straface G, Pecorini G, Stigliano E, Smith RC, Angelini F, Castellot JJ Jr, Pola R. Selective activation of peroxisome proliferator-Activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes. 2008;57:1394-1404
14. Akhtar N, Dickerson EB, Auerbach R. The sponge/Matrigel angiogenesis assay. Angiogenesis. 2002;5:75-80
15. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 1999;59:4770-4775
16. Danese S, Sans M, De La Motte C, Graziani C, West G, Phillips MH, Pola R, Rutella S, Willis J, Gasbarrini A, Fiocchi C. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006;130:2060-2073
17. Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, Isner JM. Mouse model of angiogenesis. Am J Pathol. 1998;152:1667-1679
18. Kajimoto K, Hossen MN, Hida K, Ohga N, Akita H, Hyodo M, Hida Y, Harashima H. Isolation and culture of microvascular endothelial cells from murine inguinal and epididymal adipose tissues. J Immunol Methods. 2010;357:43-50
19. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-Associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc. 2009;4: 1798-1806
20. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P, Ledda F. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest. 1994;94:2036-2044
21. Mineo C, Shaul PW. Regulation of eNOS in caveolae. Adv Exp Med Biol. 2012;729:51-62
22. Grosser N, Schröder H. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vasc Biol. 2003;23:1345-1351
23. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 1998;97: 716-720
24. Straface G, Aprahamian T, Flex A, Gaetani E, Biscetti F, Smith RC, Pecorini G, Pola E, Angelini F, Stigliano E, Castellot JJ Jr, Losordo DW, Pola R. Sonic hedgehog regulates angiogenesis and myogenesis during post-natal skeletal muscle regeneration. J Cell Mol Med. 2009;13(8B):2424-2435
25. Messina S, Mazzeo A, Bitto A, Aguennouz M, Migliorato A, De Pasquale MG, Minutoli L, Altavilla D, Zentilin L, Giacca M, Squadrito F, Vita G. VEGF overexpression via adeno-Associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice. FASEB J. 2007;21:3737-3746
26. Deasy BM, Feduska JM, Payne TR, Li Y, Ambrosio F, Huard J. Effect of VEGF on the regenerative capacity of muscle stem cells in dystrophic skeletal muscle. Mol Ther. 2009;17:1788-1798
27. Straino S, Germani A, Di Carlo A, Porcelli D, De Mori R, Mangoni A, Napolitano M, Martelli F, Biglioli P, Capogrossi MC. Enhanced arteriogenesis and wound repair in dystrophin-deficient mdx mice. Circulation. 2004;110:3341-3348
28. Tanabe Y, Esaki K, Nomura T. Skeletal muscle pathology in X chromosomelinked muscular dystrophy (mdx) mouse. Acta Neuropathol. 1986;69:91-95
29. Crosbie RH. NO vascular control in Duchenne muscular dystrophy. Nature Med. 2001:7:27-29
30. De Palma C, Clementi E. Nitric oxide in myogenesis and therapeutic muscle repair. Mol Neurobiol. 2012;46:682-692
31. Buono R, Vantaggiato C, Pisa V, Azzoni E, Bassi MT, Brunelli S, Sciorati C, Clementi E. Nitric oxide sustains long-Term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring Vangl2 and cyclic GMP. Stem Cells. 2012;30:197-209
32. Martin EA, Barresi R, Byrne BJ, Tsimerinov EI, Scott BL, Walker AE, Gurudevan SV, Anene F, Elashoff RM, Thomas GD, Victor RG. Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci Transl Med. 2012:4:162ra155
33. Khairallah M, Khairallah RJ, Young ME, Allen BG, Gillis MA, Danialou G, Deschepper CF, Petrof BJ, Des Rosiers C. Sildenafil and cardiomyocytespecific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci U S A. 2008;105:7028-7033
34. Christov C, Chrétien F, Abou-Khalil R, Bassez G, Vallet G, Authier FJ, Bassaglia Y, Shinin V, Tajbakhsh S, Chazaud B, Gherardi RK. Muscle satellite cells and endothelial cells: Close neighbors and privileged partners. Mol Biol Cell. 2007;18:1397-1409